MODERATE-TO-SEVERE ATOPIC DERMATITIS
Clinical trials for MODERATE-TO-SEVERE ATOPIC DERMATITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE-TO-SEVERE ATOPIC DERMATITIS trials appear
Sign up with your email to follow new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Eczema drug SHR-1819 put to the test in extended trial
Disease control CompletedThis study looked at the long-term safety and effectiveness of the drug SHR-1819 in 79 adults with moderate to severe atopic dermatitis (eczema) who had already taken part in earlier studies of the same drug. Researchers monitored side effects and how well the drug controlled the…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 10:40 UTC
-
New hope for eczema in skin of color: dupilumab shows promise
Disease control CompletedThis study looked at how well the drug dupilumab works for people with skin of color who have moderate-to-severe eczema (atopic dermatitis). Eczema causes itchy, dry, cracked skin. The study included 124 adolescents and adults and measured skin improvement after 24 weeks. The goa…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 10:27 UTC
-
New shot shows promise for severe eczema sufferers
Symptom relief CompletedThis study tested an experimental injection called SHR-1819 in 158 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if it could safely improve skin symptoms like redness, itching, and scaling over 16 weeks. Participants received either the drug or a …
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated May 07, 2026 18:38 UTC
-
Eczema drug may weaken vaccines: new study reveals impact
Knowledge-focused CompletedThis study looked at whether rocatinlimab, a drug for moderate-to-severe eczema, changes how well vaccines work. 221 adults with eczema received either rocatinlimab or a placebo, then got tetanus and meningococcal vaccines. The goal was to see if the drug affects the body's abili…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Amgen • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC